Washington Examiner

FDA panel backs inhaler drug for lung disease

WASHINGTON (AP) — A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of ...
Business Wire

Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ®, ANORO ® ELLIPTA ®. In addition, Innoviva retains a 15 percent economic ...
Wall Street Journal

GlaxoSmithKline Inhaler Trial Fails to Show Extension of Life

LONDON—A large clinical trial run by GlaxoSmithKline PLCGSK0.75%increase; green up pointing triangle has failed to show that the company’s Breo Ellipta inhaler extends life in patients with chronic ...
PharmaTimes

FDA panel backs GSK/Theravance inhaler for adults, not children

Breo Ellipta is already on the US market for the long-term, once-daily, maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary ...
FiercePharma

FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD

LONDON and SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory ...
KSL

FDA panel backs Glaxo inhaler for adults, not adolescents

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
FiercePharma

FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ...
Monthly Prescribing Reference

Trelegy Ellipta Improves Lung Function in Patients With Uncontrolled Asthma

Results from a phase 3 trial evaluating Trelegy Ellipta in patients with uncontrolled asthma showed that the single inhaler triple therapy provided a significant improvement in lung function when ...
Seattle Times

FDA OKs Glaxo’s inhaler, first one to combine 3 medicines

TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
Business Wire

Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

Trelegy Ellipta is a combination of three molecules in a single inhaler. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, ...
Washington Times

FDA OKs Glaxo’s inhaler, first one to combine 3 medicines

TRENTON, N.J. (AP) - The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...